Diosgenin improves post-myocardial infarction cardiac function via HAND2-induced angiogenesis

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Regenerative Medicine

Background:

• Diosgenin shows promise for cardiovascular diseases, but its role in heart attack treatment is not fully understood.
• Myocardial infarction (MI) leads to significant cardiac damage, necessitating novel therapeutic approaches.
• Angiogenesis, the formation of new blood vessels, is crucial for cardiac repair post-MI.

Purpose of the Study:

• To investigate the therapeutic effects of diosgenin on myocardial infarction (MI) in a mouse model.
• To elucidate the underlying molecular mechanisms of diosgenin's cardioprotective actions.
• To evaluate diosgenin's impact on cardiac function, fibrosis, apoptosis, and angiogenesis.

Main Methods:

• Utilized a myocardial infarction (MI) mouse model to assess diosgenin's efficacy.
• Quantified cardiac function, fibrosis, and apoptosis following diosgenin treatment.
• Investigated the role of Hand2 and its downstream targets in diosgenin-mediated angiogenesis.
• Employed endothelial cell cultures under hypoxic conditions to study cell proliferation and migration.

Main Results:

• Diosgenin significantly improved cardiac function in the MI mouse model.
• Diosgenin treatment reduced cardiac fibrosis and apoptosis.
• Diosgenin upregulated Hand2 expression, enhancing endothelial cell proliferation and migration under hypoxia.
• Diosgenin-induced angiogenesis was dependent on Hand2 activation of the Aggf1 gene.

Conclusions:

• Diosgenin demonstrates significant cardioprotective effects in a myocardial infarction model.
• Diosgenin promotes angiogenesis through the Hand2/Aggf1 pathway, improving cardiac repair.
• These findings support diosgenin as a potential therapeutic agent for heart attack treatment, validating its angiogenic properties.